The effect of livaroxaban anticoagulant therapy in the improvement of mild cognitive dysfunction in elderly patients with non-valvular atrial fibrillation
Shang Liang
Ma Qing
Wei Na
Liu Yanmei
Zhang Jing
Shi Ye
Miao Qing
Abstract：Objective To investigate the effect of livaroxaban anticoagulant therapy in the improvement of mild cognitive impairment (MCI) in elderly patients with non-valvular atrial fibrillation. Methods Patients with non-valvular atrial fibrillation and MCI were enrolled for analysis. All patients were given basic medical treatment to control blood pressure, sugar and lipid, and were divided into livaroxaban group (n=32, 10 mg per day) and aspirin group (n=20, 75 mg per day) according to the selection of anticoagulant agents after consulting with patients. The event of bleeding and thromboembolism were recorded during 1 year follow-up. Mini-mental state examination (MMSE), montreal cognitive assessment (MoCA), and activity of daily living(ADL) scores were evaluated at baseline, 6 months and 1-year follow-up in both groups. Results During 1 year follow-up, there were 2 patients with bleeding and no thromboembolism occurred in livaroxaban group; and 1 patient with bleeding and 2 patients with thromboembolism in aspirin group. The occurrence of bleeding and thromboembolism were not significantly different in both groups. MMSE, MoCA, and ADL scores in livaroxaban group and MoCA score in aspirin group evaluated in 1 year were significantly higher than those at baseline (P<0.05). MMSE, MoCA, and ADL scores in livaroxaban group were significant higher than those in aspirin group after 1 year follow-up. Conclusion Livaroxaban anticoagulant therapy can prevent thromboembolism and improve MCI in elderly patients with non-valvular atrial fibrillation.
Keywords：Non-valvular atrial fibrillationRivaroxabanMild cognitive impairmentAnticoagulation therapy
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 439-441 )